Breast Cancer Clinical Trials in New York, NY

267 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
E-Mindfulness Approaches for Living After Breast Cancer	Phase 3	NRG Oncology	<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Phase 3	National Cancer Institute (NCI)	<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Phase 2	National Cancer Institute (NCI)	<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Phase 3	NRG Oncology	<1 mi
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	Phase 1/2	Hoffmann-La Roche	<1 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain	Phase 3	NRG Oncology	<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	Phase 3	Canadian Cancer Trials Group	<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)	Phase 3	NRG Oncology	<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	Phase 3	SWOG Cancer Research Network	<1 mi
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
Factors Associated With Breast Cancer Risks and Outcomes	—	Memorial Sloan Kettering Cancer Center	<1 mi
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer	Phase 3	Memorial Sloan Kettering Cancer Center	<1 mi
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer	—	Memorial Sloan Kettering Cancer Center	<1 mi
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of a Decision Tool for People Considering Breast Reconstruction Surgery	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors	Phase 2	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer	Phase 3	NRG Oncology	<1 mi
A Study on Pain After Breast Reconstruction	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Revaree Plus in People With Breast Cancer	Phase 4	Memorial Sloan Kettering Cancer Center	<1 mi
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Blood Pressure Control During Cancer Treatment	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control	Phase 3	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors	Phase 2	AstraZeneca	<1 mi
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement	Phase 4	Memorial Sloan Kettering Cancer Center	<1 mi
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Language Interpretation Solutions for People With Breast Cancer	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol	Phase 4	Memorial Sloan Kettering Cancer Center	<1 mi
Lymphedema Surveillance Study	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Registry for People With T-cell Lymphoma	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer	Phase 1/2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Surgery and Radiotherapy in People With Breast Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial	Phase 3	NRG Oncology	<1 mi
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer	Phase 3	Hoffmann-La Roche	<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)	Phase 3	Gilead Sciences	<1 mi
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer	Phase 1/2	Stemline Therapeutics, Inc.	<1 mi
SLV-154 Treatment of Metastatic Solid Tumors	Phase 1	Solve Therapeutics	<1 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation	—	Guardant Health, Inc.	<1 mi
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation	Phase 3	AstraZeneca	<1 mi
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	Phase 3	Jazz Pharmaceuticals	<1 mi
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Phase 2	QuantumLeap Healthcare Collaborative	<1 mi
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors	Phase 1	Exelixis	<1 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence	Phase 3	Stemline Therapeutics, Inc.	<1 mi
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	Phase 3	Relay Therapeutics, Inc.	<1 mi
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	Phase 2	Rutgers, The State University of New Jersey	<1 mi
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	Phase 1	Relay Therapeutics, Inc.	<1 mi
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease	Phase 3	Pfizer	<1 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)	Phase 3	AstraZeneca	<1 mi
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer	Phase 3	AstraZeneca	<1 mi
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	Phase 2	Oana Danciu	<1 mi
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 3	Sermonix Pharmaceuticals Inc.	<1 mi
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation	Phase 1	AstraZeneca	<1 mi
A Phase 1/1b Study of IAM1363 in HER2 Cancers	Phase 1	Iambic Therapeutics, Inc	<1 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	Tizona Therapeutics, Inc	<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	—	Massive Bio, Inc.	<1 mi
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.	Phase 3	BriaCell Therapeutics Corporation	<1 mi
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs	—	NYU Langone Health	<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity	Phase 3	SWOG Cancer Research Network	<1 mi
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)	Phase 3	AstraZeneca	<1 mi
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
ATEMPT 2.0: Adjuvant T-DM1 vs TH	Phase 2	Dana-Farber Cancer Institute	<1 mi
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer	Phase 2	Dana-Farber Cancer Institute	<1 mi
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study	N/A	Weill Medical College of Cornell University	<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer	Phase 3	Novartis Pharmaceuticals	<1 mi
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery	Phase 1	SURGE Therapeutics	<1 mi
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Phase 1/2	Ascendis Pharma Oncology Division A/S	<1 mi
The Cancer of the Pancreas Screening-5 CAPS5)Study	Phase 3	Johns Hopkins University	<1 mi
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors	Phase 1	Alterome Therapeutics, Inc.	<1 mi
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies	Phase 1/2	AstraZeneca	<1 mi
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy	Phase 3	AstraZeneca	<1 mi
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer	Phase 1	Eileen Connolly	<1 mi
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	Phase 1/2	858 Therapeutics, Inc.	<1 mi
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Phase 1	Senhwa Biosciences, Inc.	<1 mi
Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients	—	Weill Medical College of Cornell University	<1 mi
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer	Phase 1	OncoTherapy Science, Inc.	<1 mi
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Phase 3	AstraZeneca	<1 mi
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Phase 1/2	ORIC Pharmaceuticals	<1 mi
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)	—	Memorial Sloan Kettering Cancer Center	<1 mi
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Phase 1	National Cancer Institute (NCI)	<1 mi
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial	Phase 2	Massachusetts General Hospital	<1 mi
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.	Phase 1/2	RayzeBio, Inc.	<1 mi
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors	Phase 1	Bristol-Myers Squibb	<1 mi
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	—	Agendia	<1 mi
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy	Phase 3	Proton Collaborative Group	<1 mi
Breast Elasticity Imaging During Neoadjuvant Chemotherapy	N/A	Columbia University	<1 mi
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)	Phase 3	Celcuity Inc	<1 mi
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer	N/A	Icahn School of Medicine at Mount Sinai	<1 mi
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer	Phase 2	Proton Collaborative Group	<1 mi
IMPACT Trial: Intervention to iMProve AdherenCe Equitably	N/A	Columbia University	<1 mi
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)	Phase 1	H. Lee Moffitt Cancer Center and Research Institute	<1 mi
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors	N/A	The New York Proton Center	<1 mi
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer	Phase 1	Olema Pharmaceuticals, Inc.	<1 mi
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer	Phase 2	MedSIR	<1 mi
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts	N/A	American College of Radiology	<1 mi
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	Phase 1/2	Colette Shen	<1 mi
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Phase 3	Greenwich LifeSciences, Inc.	<1 mi
A Study of LY4257496 in Participants With Cancer (OMNIRAY)	Phase 1	Eli Lilly and Company	<1 mi
Two Versus One Week Breast Radiotherapy (RT)	Phase 3	Weill Medical College of Cornell University	<1 mi
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)	N/A	University of California, San Francisco	<1 mi
A Study of XMT-1660 in Participants With Solid Tumors	Phase 1	Mersana Therapeutics	<1 mi
Combined Immunotherapies in Metastatic ER+ Breast Cancer	Phase 2	Weill Medical College of Cornell University	<1 mi
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer	Phase 3	AstraZeneca	<1 mi
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)	N/A	University Health Network, Toronto	<1 mi
A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania	—	Memorial Sloan Kettering Cancer Center	<1 mi
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients	—	Memorial Sloan Kettering Cancer Center	<1 mi
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors	Phase 1/2	Tubulis GmbH	<1 mi
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	Phase 1/2	Eli Lilly and Company	<1 mi
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread	Phase 1/2	Boehringer Ingelheim	<1 mi
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
Optimizing Surgical Decisions in Young Adults With Breast Cancer	N/A	Weill Medical College of Cornell University	<1 mi
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)	Phase 2/3	Bristol-Myers Squibb	<1 mi
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	Phase 2	National Cancer Institute (NCI)	<1 mi
Study of INCB123667 in Subjects With Advanced Solid Tumors	Phase 1	Incyte Corporation	<1 mi
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You	—	Weill Medical College of Cornell University	<1 mi
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer	Phase 2	BicycleTx Limited	<1 mi
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer	Phase 1/2	Icahn School of Medicine at Mount Sinai	<1 mi
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)	N/A	Columbia University	<1 mi
Treatment of Breast Fibroadenoma Targeted Tissue With HIFU	N/A	Theraclion	<1 mi
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer	Early 1	Rima Patel	<1 mi
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients	Phase 1/2	Weill Medical College of Cornell University	<1 mi
Converting HR+ Breast Cancer Into an Individualized Vaccine	Phase 2	Weill Medical College of Cornell University	<1 mi
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery	Phase 1/2	Memorial Sloan Kettering Cancer Center	<1 mi
Study of AVZO-021 in Patients With Advanced Solid Tumors	Phase 1/2	Avenzo Therapeutics, Inc.	<1 mi
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients	N/A	Columbia University	<1 mi
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	Phase 3	Eli Lilly and Company	<1 mi
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
Mammography and Breast Arterial Calcification: An Information-Sharing Trial	N/A	Icahn School of Medicine at Mount Sinai	<1 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A	SWOG Cancer Research Network	<1 mi
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors	Phase 1/2	Avenzo Therapeutics, Inc.	<1 mi
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida	—	Memorial Sloan Kettering Cancer Center	<1 mi
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)	Phase 2	Criterium, Inc.	<1 mi
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours	Phase 1	Avacta Life Sciences Ltd	<1 mi
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer	Phase 4	Weill Medical College of Cornell University	<1 mi
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	Phase 3	Olema Pharmaceuticals, Inc.	<1 mi
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc	N/A	Columbia University	<1 mi
An Ophthalmic Safety Study in Patients With Breast Cancer	—	AstraZeneca	<1 mi
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	Phase 2	QuantumLeap Healthcare Collaborative	<1 mi
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs	Phase 1	Mabwell (Shanghai) Bioscience Co., Ltd.	<1 mi
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer	Phase 1	Deborah Doroshow	<1 mi
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells	Phase 1	General Oncology, Inc.	<1 mi
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	Phase 1	MOMA Therapeutics	<1 mi
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer	Phase 1/2	BioNTech SE	<1 mi
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Phase 1/2	Novartis Pharmaceuticals	<1 mi
Pancreatic Cancer Genetics	—	Columbia University	<1 mi
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer	—	Sir Mortimer B. Davis - Jewish General Hospital	<1 mi
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors	Phase 1	Cogent Biosciences, Inc.	<1 mi
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies	Phase 1	Janux Therapeutics	<1 mi
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Phase 1/2	Bristol-Myers Squibb	<1 mi
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors	Phase 1	Innate Pharma	<1 mi
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies	Phase 1/2	AstraZeneca	<1 mi
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors	Phase 1	Aktis Oncology, Inc.	<1 mi
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression	Phase 1/2	A2 Biotherapeutics Inc.	<1 mi
A Study of Mental Health Care in People With Cancer	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types	Phase 1/2	Eisai Inc.	<1 mi
A Study of LY4175408 in Participants With Advanced Cancer	Phase 1	Eli Lilly and Company	<1 mi
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing	—	A2 Biotherapeutics Inc.	<1 mi
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Phase 1	Clasp Therapeutics, Inc.	<1 mi
Study of DF1001 in Patients with Advanced Solid Tumors	Phase 1/2	Dragonfly Therapeutics	<1 mi
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors	Phase 1	SystImmune Inc.	<1 mi
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2	Phase 1	Mersana Therapeutics	<1 mi
National Cancer Institute "Cancer Moonshot Biobank"	—	National Cancer Institute (NCI)	<1 mi
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors	Phase 1	SystImmune Inc.	<1 mi
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 2	Daiichi Sankyo	<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors	Phase 1	IDEAYA Biosciences	<1 mi
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/2	Volastra Therapeutics, Inc.	<1 mi
Study of Oral MRT-2359 in Selected Cancer Patients	Phase 1/2	Monte Rosa Therapeutics, Inc	<1 mi
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Phase 1/2	PMV Pharmaceuticals, Inc	<1 mi
Comprehensive Outcomes for After Cancer Health	N/A	Pack Health	<1 mi
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	Phase 1	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	<1 mi
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)	Phase 1/2	GI Innovation, Inc.	<1 mi
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials	N/A	Icahn School of Medicine at Mount Sinai	<1 mi
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Phase 1	Nammi Therapeutics Inc	<1 mi
Brodalumab in the Treatment of Immune-Related Adverse Events	Phase 1	Brian Henick, MD	<1 mi
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)	Phase 2	Daiichi Sankyo	<1 mi
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors	Phase 1/2	Tango Therapeutics, Inc.	<1 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted	Phase 2	Rutgers, The State University of New Jersey	4 mi
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment	Phase 4	Rutgers, The State University of New Jersey	4 mi
Mobile Health for Adherence in Breast Cancer Patients	N/A	ECOG-ACRIN Cancer Research Group	5 mi
The PREDICT Registry:	—	PreludeDx	5 mi
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer	Phase 2	Rutgers, The State University of New Jersey	9 mi
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer	Phase 2	Jazz Pharmaceuticals	9 mi
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers	N/A	Beth Israel Deaconess Medical Center	9 mi
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole	Phase 1	Mridula George, MD	9 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics	—	Wake Forest University Health Sciences	11 mi
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)	Phase 3	Hoffmann-La Roche	11 mi
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy	N/A	Wake Forest University Health Sciences	12 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials	N/A	Eastern Cooperative Oncology Group	12 mi
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies	Early 1	Presage Biosciences	12 mi
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd	Phase 2	Ana C Garrido-Castro, MD	12 mi
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer	—	Abramson Cancer Center at Penn Medicine	12 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab	Phase 3	Alliance for Clinical Trials in Oncology	12 mi
CDK and Body Composition Study	—	Montefiore Medical Center	12 mi
Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery	N/A	Albert Einstein College of Medicine	12 mi
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia	Phase 1	SillaJen, Inc.	12 mi
Intra-Operative Radiation Registry	—	Albert Einstein College of Medicine	12 mi
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer	N/A	Montefiore Medical Center	12 mi
EXoPERT EMERALD Clinical Study	—	EXoPERT	12 mi
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)	—	Exact Sciences Corporation	12 mi
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)	Phase 3	Merck Sharp & Dohme LLC	12 mi
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)	Phase 3	Merck Sharp & Dohme LLC	12 mi
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Phase 3	Hoffmann-La Roche	12 mi
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer	Phase 1/2	Georgetown University	12 mi
A Phase 1 Study of LNCB74 in Advanced Solid Tumors	Phase 1	NextCure, Inc.	12 mi
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	Phase 1	NiKang Therapeutics, Inc.	12 mi
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors	Phase 1/2	Bristol-Myers Squibb	12 mi
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)	Phase 3	DualityBio Inc.	13 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors	N/A	NRG Oncology	13 mi
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study	Phase 2	GlaxoSmithKline	16 mi
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors	Phase 1/2	Aminex Therapeutics, Inc.	16 mi
A Study of MGC026 in Participants With Advanced Solid Tumors	Phase 1	MacroGenics	16 mi
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors	Phase 1/2	Astellas Pharma Global Development, Inc.	17 mi
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs	—	SpotitEarly	17 mi
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer	Phase 3	Daiichi Sankyo	19 mi
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors	N/A	Novian Health Inc.	21 mi
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy	Phase 2	BioNTech SE	22 mi
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	Phase 2	Processa Pharmaceuticals	22 mi
Rutgers University Study of the Genetics of Breast Cancer.	—	Rutgers, The State University of New Jersey	25 mi
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)	Phase 1/2	Merck Sharp & Dohme LLC	28 mi
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer	N/A	Rutgers, The State University of New Jersey	28 mi
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer	Phase 1/2	Genentech, Inc.	28 mi
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer	Phase 1	Christian Hinrichs	28 mi
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer	Phase 1	Stemline Therapeutics, Inc.	29 mi
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer	Phase 2	Hoffmann-La Roche	29 mi
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors	Phase 1/2	MBrace Therapeutics	29 mi
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors	Phase 1	BeiGene	29 mi
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	Phase 3	American Society of Clinical Oncology	29 mi
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.	Phase 3	Pfizer	29 mi
Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy	N/A	Virtua Health, Inc.	30 mi
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy	N/A	M.D. Anderson Cancer Center	30 mi
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC	Phase 2	Dana-Farber Cancer Institute	34 mi
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer	Phase 1/2	Hoffmann-La Roche	34 mi
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer	Phase 1	Radionetics Oncology	43 mi
CtDNA Based MRD Testing for NAC Monitoring in TNBC	—	Personalis Inc.	48 mi
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer	Phase 1	OnKure, Inc.	48 mi
Definitive Radiation Therapy for Inoperable Breast Cancer	N/A	Alexander Stessin	48 mi
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer	Early 1	Alison Stopeck	48 mi
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases	Phase 2	Biostar Pharma, Inc.	48 mi
Definitive Radiation for High-Risk Spine Metastases	Phase 2	Stony Brook University	48 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.